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Type 1 diabetes (T1D) is an autoimmune disease resulting from
defects in central and peripheral tolerance and characterized by T
cell-mediated destruction of islet  cells. Cytotoxic CD8 T cells,
reactive to  cell antigens, are required for T1D development in the
NOD mouse model of the disease, and CD8 T cells specific for  cell
antigens can be detected in the peripheral blood of T1D patients.
It has been evident that in nonautoimmune-prone mice, dendritic
cells (DCs) present model antigens in a tolerogenic manner in the
steady state, e.g., in the absence of infection, and cause T cells to
proliferate initially but then to be deleted or rendered unrespon-
sive. However, this fundamental concept has not been evaluated
in the setting of a spontaneous autoimmune disease. To do so, we
delivered a mimotope peptide, recognized by the diabetogenic
CD8 T cell clone AI4, to DCs in NOD mice via the endocytic receptor
DEC-205. Proliferation of transferred antigen-specific T cells was
initially observed, but this was followed by deletion. Tolerance
was achieved because rechallenge of mice with the mimotope
peptide in adjuvant did not induce an immune response. Thus,
targeting of DCs with  cell antigens leads to deletion of autore-
active CD8 T cells even in the context of ongoing autoimmunity
in NOD mice with known tolerance defects. Our results provide
support for the development of DC targeting of self antigens for
treatment of chronic T cell-mediated autoimmune diseases.
autoimmune disease  type 1 diabetes
Type 1 diabetes (T1D) is an autoimmune disease characterizedby an inability to establish and maintain tolerance to  cell
antigens. In diabetes-prone individuals, autoreactive T cells
respond to pancreatic islet  cell antigens in conjunction with
costimulatory signals, promoting initial T cell activation result-
ing in selective expansion, differentiation, islet invasion, and
ultimately destruction of  cells (1). Clinically, the end result is
the inability of the affected individual to produce the insulin
required to properly regulate glucose metabolism. NOD mice
provide a model system for T1D that shares many of the
characteristics of the human disease (2). Multiple lines of
investigation have demonstrated the importance of CD8 T cells
in the pathogenesis of T1D in NOD mice (3). This is consistent
with the detection of islet antigen-specific CD8 T cells in the
peripheral blood of T1D patients (4). Using CD8 T cells
derived from the islets of NOD mice, a limited number of  cell
antigens recognized by islet-infiltrating T cells have been iden-
tified (4). Lack of availability of a therapy for T1D other than
insulin administration inspires the usage of  cell antigens and
epitopes targeted by T cells in T1D to develop antigen-based
tolerogenic strategies.
As reviewed (5), dendritic cells (DCs) in the steady state, e.g.,
in the absence of infection, present antigens in a tolerogenic
manner and cause naive CD8 T cells to proliferate initially but
then to be deleted or rendered unresponsive. The pathway by
which DCs acquire exogenous antigens and process them directly
for display on class I MHC molecules is known as cross-
presentation. DEC-205 (CD205), an endocytic receptor with 10
membrane-external contiguous C-type lectin domains (6), is
expressed at high levels on DCs in the T cell areas of lymphoid
organs and is one of the DC surface receptors that facilitates this
process (7). Like naive T cells, antigen-experienced, including
memory, CD8 T cells are also subject to peripheral tolerance
in response to cross-presented antigen (8). Processing and
presentation of self antigens by steady-state DCs are now
thought to be major components of the establishment of toler-
ance in the periphery. Interestingly, autoimmune-prone NOD
mice have several reported defects in DC populations, including
a deficiency in the number of DEC-205 DCs (9–12).
Antigens can be experimentally targeted to DCs in vitro or in
vivo via the DEC-205 receptor by introducing antigen into an
antibody to the receptor (13–16), and this increases the efficiency
of presentation of antigens on both MHC class I and class II
products in vivo (13, 15, 17, 18). Selective presentation in the
steady state of a foreign antigen by DCs in vivo leads to deletion
of reactive CD8 T cells and the establishment of tolerance in
nonautoimmune-prone C57BL/6 mice (13, 19). Selective DC-
based presentation of a natural self antigen to CD8 T cells in
the setting of a spontaneous autoimmune disease has yet to be
explored but is of considerable biological and clinical interest.
Here, we have used targeted delivery of a mimotope of a  cell
peptide to DEC-205 in NOD mice and have found that CD8 T
cell tolerance could be achieved even in the face of ongoing
autoimmunity and in mice with multiple reported tolerance
defects (20–23) and DC abnormalities (9–12).
Results
Preparation and Characterization of a Hybrid Antibody to Be Used for
the Tolerization of  Cell-Autoreactive CD8 T Cells. AI4 is a
pathogenic CD8 T cell clone, isolated from the islets of a
5-wk-old female NOD mouse capable of mediating T1D in the
absence of CD4 T cell help (24). AI4 T cells recognize the
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superagonist peptide MimA2 in the context of the class I MHC
molecule H-2Db (25). We constructed a hybrid anti-DEC-205
antibody linked with MimA2 [designated anti-DEC-205/
MimA2; see Materials and Methods and supporting information
(SI) Fig. S1 A] to develop a strategy to manipulate  cell-
autoreactive CD8 T cells in the context of a spontaneous
autoimmune disease. The hybrid and unmodified antibodies
bound similarly to a stably transfected CHO cell line expressing
DEC-205 on its surface (Fig. S1B).
To determine whether antigen delivered by anti-DEC-205 can
be processed for presentation to CD8 T cells, we purified
CD11c DCs and CD11c cells from the spleens of NOD mice
and incubated them overnight with anti-DEC-205/MimA2 or a
control Ig, also fused to MimA2 but unable to bind DEC-205
(control Ig/MimA2). The antigen-presenting cells (APCs) were
then cocultured for 2 d with MimA2-specific CD8 AI4 T cells
purified from NOD.AI4Tg mice, and T cell proliferation was
monitored by [3H]thymidine incorporation. The DCs treated
with anti-DEC-205/MimA2 selectively stimulated AI4 T cell
proliferation, whereas those treated with control Ig/MimA2
were less active (Fig. 1). The hybrid anti-DEC-205 antibody
therefore enhances cross-presentation of the diabetogenic
MimA2 epitope by DCs.
Anti-DEC-205 Antibody Delivers a Superagonist Mimotope of a  Cell
Antigen for Presentation on Class I MHC in Vivo. To determine
whether anti-DEC-205/MimA2 could be used for in vivo delivery
of the MimA2 peptide, we transferred carboxyf luorescein
diacetate succinimidyl ester (CFSE)-labeled Thy1b AI4 T cells to
NOD.NON-Thy1a recipients and then treated these recipients
with anti-DEC-205/MimA2 or control Ig/MimA2. After 3 d,
peripheral lymph nodes, pancreatic lymph nodes, and spleens
were harvested and stained with anti-Thy1.2 and -CD8 to
identify the transferred cells for examination by flow cytometry
(Fig. 2A). Extensive proliferation was observed in the peripheral
lymph nodes and spleens of anti-DEC-205/MimA2-treated an-
imals (with 64  19% and 65  28% of cells showing CFSE
dilution, respectively; n  2), but far less in animals treated with
control Ig/MimA2 (26  15% and 24  13%) or PBS (16  9.2%
and 13  3.5%). However, all mice showed T cell proliferation
in their pancreatic lymph nodes because of endogenous presen-
tation of AI4’s natural  cell antigen at this site (26).
Because AI4 T cells recognize a  cell antigen and cause T1D
in NOD.AI4 Tg mice (24), it is possible that the transferred
T cells had previously been exposed to their antigen and were not
naive. Furthermore, at least some of the transferred cells were
clearly exposed to their natural antigen in the pancreatic lymph
nodes of the recipient mice (Fig. 2 A). To confirm that peptide-
linked anti-DEC-205 is alone sufficient to stimulate the prolif-
eration of NOD T cells, even if naive, we used T cells from
NOD.LCMV TCR Tg mice (27), which are specific for a peptide
derived from lymphocytic choriomeningitis virus (LCMV) gly-
coprotein (GP33–41) presented by H-2Db. These mice serve as a
source of purely naive splenocytes, because the LCMV protein
is not expressed in these animals. We transferred CFSE-labeled
Thy1.2 CD8 LCMV-specific T cells to NOD.NON-Thy1a
recipients and treated the recipients with anti-DEC-205/GP33–41.
As shown in Fig. 2B, after 3 d, extensive T cell proliferation was
observed in the peripheral lymph nodes, pancreatic lymph nodes,
and spleens of the treated mice (with 51  28%, 59  13%, and
54  15% of cells showing CFSE dilution, respectively; n  2)
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Fig. 1. Presentation of peptides derived from anti-DEC-205/MimA2 is re-
stricted to CD11c cells in vitro. Splenic DCs (CD11c cells) (Left) or CD11c cells
(Right) were isolated from NOD mice and incubated overnight with the
indicated antibodies. CD8 T cells were purified from the spleens of
NOD.AI4Tg mice, and 5  104 AI4 T cells were incubated at the indicated
ratios with APCs in 96-well plates. After 3 d of coculture, proliferation was
monitored by [3H]thymidine incorporation. Data shown are representative of
at least two similar experiments. Significant differences between correspond-









































































































































Fig. 2. In vivo targeting of peptide-linked anti-DEC-205 results in similar
proliferation of CD8 T cells specific for a self or foreign peptide.
NOD.NON.Thy1a mice were injected i.v. with (A) 2  106 CFSE-labeled AI4 T
cells purified from NOD.AI4Tg mice or (B) 2  106 CFSE-labeled CD8 T cells
purified from NOD.LCMV TCR Tg mice. Twenty-four hours later, recipient mice
were treated i.p. with (A) 10 g of anti-DEC-205/MimA2 or control Ig/MimA2
or PBS, or (B) 10 g of anti-DEC-205/GP33–41 or PBS. Three days after hybrid
antibody injection, lymphoid organs were harvested, and the proliferation of
Thy1.2 CD8 cells was evaluated by flow cytometry for CFSE dilution. Data
shown are representative of at least two experiments.









































1.2  0.54%). These results indicate that peptide-linked anti-
DEC-205 is alone sufficient to induce the proliferation of naive
NOD T cells, even when the dose of injected peptide is relatively
small, 20 ng per mouse.
DCs Are Required for the in Vivo Activity of Antigen-Linked Anti-DEC-
205 Antibodies. Although DEC-205 is expressed at high levels by
a subset of DCs, it is also expressed by a number of other cell
types in situ such as thymic and intestinal epithelia, follicular B
cells, bone marrow stromal cells, and pulmonary airway epithelia
(7). To establish the importance of DCs here, we developed
NOD.CD11c-DTR.Thy1a mice. These mice carry a transgene
encoding a simian diphtheria toxin (DT) receptor (DTR)-GFP
fusion protein under the control of the murine CD11c promoter,
which is active in nearly all murine DC subsets. As reported for
FVB/N mice carrying this transgene (28), use of 4 ng/g of DT
selectively depleted CD11c cells in the NOD.CD11c-DTR mice
(Fig. 3A), and the toxin-induced DC depletion persisted for 2 d,
after which DC numbers were gradually restored (data not
shown). It has been reported that marginal zone macrophages
are also depleted upon DT treatment in mice expressing the
CD11c-DTR transgene (29); however, because these cells do not
express DEC-205 (7), they need not be considered here. CFSE-
labeled Thy1.2 AI4 cells (2  106) were injected i.v. into
NOD.CD11c-DTR.Thy1a mice, and 16 h later, we injected 4 ng/g
DT i.p. followed 8 h later by 10 g of anti-DEC-205/MimA2 i.p.
After 3 d, T cell proliferation was found to be dramatically
reduced in the lymphoid tissues of DT-treated mice (Fig. 3B),
indicating that DCs are required for DEC-205-mediated cross-
presentation of antigen via class I MHC. Some proliferation of
transferred AI4 T cells was observed in the pancreatic lymph
nodes of DT-treated mice but not in the peripheral lymph nodes
or spleen. This is likely due to partial recovery of DCs 3 days
after DT treatment, as has been reported by others (28). The
proliferation is selective for the pancreatic lymph node, because
presentation of AI4’s endogenous  cell antigen occurs only at
this site (Fig. 2 A Lower).
Transferred  Cell-Autoreactive CD8 T Cells Are Eventually Deleted
in Response to Antigen Targeting via DEC-205. To test whether
treatment of NOD mice with anti-DEC-205/MimA2 would
result in the eventual deletion of transferred AI4 T cells, we
again transferred these cells to NOD.NON-Thy1a mice and
injected either anti-DEC-205/MimA2 or control Ig/MimA2.
This time, however, we looked for the AI4 T cells after 12 rather
than 3 d (Fig. 4A). In the peripheral lymph nodes, pancreatic
lymph nodes, and spleens of mice treated with anti-DEC-205/
MimA2, the transferred AI4 T cells constituted a smaller

















































































Fig. 3. In vivo DC depletion blocks CD8 T cell proliferation in response to
anti-DEC-205/MimA2. NOD.CD11c-DTR.Thy1a mice were injected i.v. with 2 
106 CFSE-labeled AI4 T cells and 16 h later with 4 ng/g DT i.p. or PBS. Eight hours
after the DT or PBS injection, recipient mice were given 10 g of anti-DEC-
205/MimA2 i.p. (A) Three days after antibody treatment, spleens were disso-
ciated with collagenase D and the CD11c CD8 and CD11c CD8 DC subsets
were identified after enrichment into a low-density cell fraction and analysis
by flow cytometry, with samples gated on B220 CD3 cells. (B) Lymphoid
organs were harvested to evaluate the proliferation of Thy1.2 CD8 AI4 T














































































































































Fig. 4. Anti-DEC-205/MimA2 targeting of DCs in vivo leads to deletion of AI4
T cells. (A) NOD.NON.Thy1a mice were injected i.v. with 2  106 AI4 T cells from
NOD.AI4Tg mice and, after 24 h, i.p. with 10 g of anti-DEC-205/MimA2 or
control Ig/MimA2. Twelve days later, lymphoid organs of recipient mice were
harvested, and Thy1.2 CD8 cells were enumerated by flow cytometry. (B)
Same as in A, but the transferred T cells were from NOD.Rag1null. AI4Tg
mice. (C) The pancreata of the same mice used in B were perfused and islets
were picked and cultured for 2 d. Islet infiltrates were harvested and evaluated
for Thy1.2 CD8 cells by flow cytometry. In A-C, numbers denote the per-
centage of CD8 cells present in the indicated gates. Data shown are repre-
sentative of at least two experiments.

































treated animals. This analysis indicated that AI4 T cells were
largely, although not completely, deleted as a result of anti-
DEC-205/MimA2 treatment.
It has been reported that approximately one-quarter of the
CD8 T cells in NOD.AI4Tg mice express the transgenic TCR
 chain at a greatly reduced level because of coexpression of
endogenous  chains (20). We reasoned that such T cells would
respond poorly, if at all, to MimA2 and would fail to be deleted
in response to treatment with anti-DEC-205/MimA2. In support
of this idea, when we transferred purified CD8 T cells from
NOD.Rag1null.AI4Tg mice, we observed essentially complete
deletion of transferred cells from lymph nodes and spleen after
12 d in response to anti-DEC-205/MimA2 treatment (Fig. 4B).
In the mice treated with anti-DEC-205/MimA2, the transferred
cells constituted 0.0014  0.0024% of CD8 cells in peripheral
lymph nodes, 0.0012  0.0018% in pancreatic lymph nodes, and
0.0014  0.0024% in spleen (n  3). The corresponding values
for control Ig/MimA2-treated mice were 0.076  0.021%, 0.17 
0.078%, and 0.063  0.0053%, respectively.
As it was possible that the transferred AI4 T cells had migrated
to the islets rather than undergoing true deletion, we isolated the
pancreatic islets on day 12 and cultured the islet infiltrate for 2 d.
The cells were then harvested, stained for Thy1.2 and CD8, and
analyzed by flow cytometry (Fig. 4C). In control Ig/MimA2-
treated animals, we observed enrichment of the transferred cells
in the islet infiltrate, where they constituted 8.6  5.0% of CD8
T cells (n  2), whereas in mice treated with anti-DEC-205/
MimA2, few transferred cells were observed in the infiltrate
(0.096  0.0057%). These findings confirmed that AI4 T
cells were largely deleted as a result of anti-DEC-205/MimA2
treatment.
Antigen Targeting to DCs via DEC-205 Induces Peripheral CD8 T Cell
Tolerance. A critical criterion for the induction of tolerance is
the inability to respond to rechallenge with antigen delivered
together with a strong adjuvant. To determine whether anti-
DEC-205/MimA2-treated NOD mice became tolerant to
MimA2, we transferred 2  106 Thy1.2 CD8 AI4 T cells or
Thy1.2 CD8 Rag1null AI4 T cells to NOD.NON-Thy1a mice.
Twelve days after administration of 10 g of anti-DEC-205/
MimA2, mice were immunized with 50 g of MimA2 peptide
suspended in CFA. Three days after CFA/peptide immuniza-
tion, the peripheral lymph node cells were harvested, and the
immune response was evaluated by intracellular cytokine
staining for IFN- production in response to in vitro stimula-
tion with MimA2. IFN--producing cells were not detectable
from mice treated 12 d earlier with anti-DEC-205/MimA2,
regardless of whether the transferred AI4 cells were from
Rag1-positive (Fig. 5A) or -negative donors (Fig. 5B). In
contrast, mice treated with PBS (data not shown), control
Ig/MimA2 (Fig. 5 A and B), or a combination of anti-DEC-
205/MimA2 and immunogenic DC maturation stimuli (anti-
CD40 and poly I:C) (Fig. 5B) produced strong IFN- re-
sponses. Thus, targeting of MimA2 to DCs via DEC-205
results in T cell tolerance, provided the antigen is not admin-
istered in combination with DC maturation stimuli.
Discussion
Bonifaz et al. (13) reported that treatment of C57BL/6 mice with
anti-DEC-205 chemically coupled to the ovalbumin protein
causes proliferation of transferred ovalbumin-specific CD8 T
cells, followed by the establishment of deletional tolerance.
However, for several reasons, it was unclear whether similar
findings would be obtained upon treatment of NOD mice with
anti-DEC-205/MimA2. First, deficiencies in central and periph-
eral tolerance mechanisms, including defects in CD8 T cell
peripheral tolerance, have been described in NOD mice (20–23).
Lack of response to a transplantation tolerance induction pro-
tocol has similarly been reported for this strain (30), and DC
defects have also been noted (9–12). Furthermore, the T1D-
susceptible NOD mouse recipients used in our work were
mounting immune responses to  cell antigens, including AI4’s
target, during the experimental period, as evidenced by infil-
trating autoreactive T cells in their islets (Fig. 4C). This is a very
different situation from that present in the nonautoimmune-
prone mice used by Bonifaz et al. (13). Also, in this previous
work, the antigen under study was a foreign one, virtually
ensuring that the transferred ovalbumin-specific T cells would be
naive. This is unlikely to be the case in our experiments, where
the AI4 T cells are harvested from T1D-susceptible
NOD.AI4Tg mice. As a result, our finding that DCs can
mediate T cell tolerance in NOD mice with known DC and
tolerance defects could not have been predicted from the
existing literature. Furthermore, the finding that DCs can me-
diate T cell tolerance even in the context of a spontaneous,
ongoing autoimmune condition could have significant biological
and therapeutic implications.
When Hogquist and coworkers (31) engineered C57BL/6
mice in which a class I MHC-binding peptide was presented by
both activating and tolerogenic DCs in a single animal, trans-
ferred peptide-specific T cells failed to accumulate, indicating
that tolerance dominated. We speculate that, because anti-
DEC-205/MimA2 gained access to peripheral lymph nodes
and spleen in addition to the pancreatic lymph nodes in our
experiments (Fig. 2), tolerance was similarly able to predom-
inate over ongoing autoimmunity. The mechanism(s) respon-
sible for this tolerance induction will be the subject of future
work. In particular, we hypothesize that the PD-1 pathway (32)



































































Fig. 5. In vivo targeting of DCs with anti-DEC-205/MimA2 induces tolerance
to MimA2. (A) NOD.NON.Thy1a mice were injected i.v. with 2  106 AI4 T cells
from NOD.AI4Tg mice and i.p. with 10 g of anti-DEC-205/MimA2 or control
Ig/MimA2. Twelve days after hybrid antibody administration, mice were
boosted with 50 g of MimA2 peptide in CFA. Three days later, peripheral
lymph nodes were harvested and stimulated with free MimA2 peptide and AI4
T cells evaluated for production of intracellular IFN-. (B) Same as in A, but the
transferred T cells were from NOD.Rag1null.AI4Tg mice and the recipient
mice were given anti-DEC-205/MimA2 i.p. with or without anti-CD40 (25 g)
and poly I:C (50 g).









































Broek and coworkers (19), using DIETER (DC-specific in-
ducible expression of T cell epitopes by recombination) mice,
showed that peripheral CD8 T cell tolerance induced by
steady-state DCs is T cell-intrinsic and deletional and requires
PD-1 on T cells (19).
With our currently available anti-DEC-205 reagents, it is not
feasible to monitor the impact of peptide-linked anti-DEC-205
treatment on endogenous T cells (as opposed to transferred
ones) in NOD mice, because the low prevalence of the MimA2
specificity (33, 34) would make it very difficult to draw mean-
ingful conclusions. Endogenous T cells will be examined once we
have developed reagents to target cells specific for residues
206–214 of islet-specific glucose-6-phosphatase catalytic sub-
unit-related protein, which is a far more prevalent specificity (33,
34). Clearly, prevention and intervention studies will also need
to be conducted in mice before exploration of antigen-linked
anti-DEC-205 as a potential therapeutic strategy for human
T1D. Our next step will involve optimization of multiple param-
eters (including antibody dose, number of treatments, and the
time relative to T cell transfer at which antibody treatment is
begun) and determination of the ability of anti-DEC-205/
MimA2 therapy to prevent T1D in an adoptive transfer model
of AI4-induced disease (26).
In summary, NOD mice have a variety of defects that interfere
with the establishment or maintenance of T cell tolerance and
lead to the spontaneous development of T1D (20–23). Here, we
demonstrate that targeting of a peptide antigen to DEC-205
DCs in vivo allows these defects to be overcome, even in the
context of ongoing  cell autoimmunity, and permits the estab-
lishment of deletional tolerance.
Materials and Methods
Mice. NOD.AI4 Tg (24) and NOD.Rag1null.AI4Tg mice (35) express the TCR
from the NOD-derived H-2Db-restricted diabetogenic CD8 T cell clone AI4
(24). NOD.LCMV TCR Tg mice (27) express an H-2Db-restricted TCR specific for
LCMV GP33–41. Fully T1D-susceptible NOD.NON-Thy1a mice have been de-
scribed (36). To generate a NOD stock carrying a DTR transgene driven by the
CD11c promoter, B6.CD11c-DTR mice (28) were backcrossed to NOD for at
least eight generations. An Idd sweep was performed, and the congenic
region linked to the transgene was found to partially overlap Idd5. Linkage
markers delineating all other known Idd loci have been fixed to homozygosity
for NOD alleles in the strain now designated NOD.CD11c-DTR. Intercrossing of
NOD.CD11c-DTR and NOD.NON-Thy1a mice was used to obtain the
NOD.CD11c-DTR.Thy1a strain used for the current studies. All mice were bred
under specific pathogen-free conditions at the Albert Einstein College of
Medicine following protocols approved by the Institutional Animal Care and
Use Committee.
Hybrid Antibody Production. Previously, the V regions of NLDC-145 (rat anti-
mouse DEC-205) and GL117 (an isotype match for NLDC-145) were cloned in
frame with the mouse Ig or mouse IgG1 constant region having mutations
that interfere with FcR binding (15). To create anti-DEC-205/MimA2 and
control Ig/MimA2, we fused these previously described heavy chains to MimA2
(YAIENYLEL) (25) flanked by the sequences naturally flanking the H-2Kb-






and these flanking regions were cloned in frame with the C terminus of the
heavy chain of anti-DEC-205. Anti-DEC-205/GP33–41 was similarly prepared by
using oligonucleotides encoding LCMV GP33–41 (KAVYNFATC). Hybrid anti-
bodies were produced by transient transfection of 293T cells by using calcium
phosphate as described in ref. 15. Cells were grown in serum-free DMEM
supplemented with Nutridoma SP (Roche). Seven to 10 d after transfection,
antibodies were purified on Protein G affinity columns (Amersham Pharma-
cia). Antibody concentrations were determined by the Bradford method
(BioRad) by using bovine -globulin as a standard.
Antibodies. Monoclonal antibodies to murine Thy1.1 (OX-7), Thy1.2 (53–2.1),
CD8 (53–6.7), CD40 (HM40–3), CD3 (145–2C11), B220 (RA3–6B2), and IFN-
(XMG1.2) and polyclonal goat anti-mouse IgG  IgM were purchased from BD
Biosciences. Magnetic microbeads and antibodies for purification of CD11c
and CD8 cells were purchased from Miltenyi Biotec.
Isolation of DCs and in Vitro T Cell Proliferation Assay. Spleens were removed
from adult female NOD mice. Single-cell suspensions were prepared with 400
units/ml collagenase D for 25 min (Roche). After low-density cell enrichment
using 30% BSA (Sigma–Aldrich), the cells were incubated with anti-mouse
CD11c MACS microbeads (Miltenyi Biotec) for 30 min on ice. CD11c (DC-
enriched) and CD11c cells were separated by application of a magnetic field
and dispensed into 96-well plates on day 0. Cells were cultured with anti-DEC-
205/MimA2 or control Ig/MimA2 overnight (16–20 h) at 37°C. On day 1, CD8
AI4 T cells were purified from single-cell suspensions of NOD.AI4Tg mouse
spleens by negative selection using MACS microbeads (Miltenyi Biotec). T cells
(5  104) were added to graded doses of CD11c or CD11c cells in round-
bottom 96-well plates. [3H]thymidine (1 Ci; GE Healthcare) was added 72 h
later, and its incorporation into DNA was measured after 8–16 h by using an
automated cell harvester.
In Vivo T Cell Proliferation and Deletion Assays. CD8 AI4 T cells were purified
from spleens of NOD. AI4Tg or NOD.Rag1null.AI4Tg mice (as indicated)
and incubated at 107 cells per ml with 5 M CFSE (Invitrogen) for 10 min at
37°C. An equal volume of FCS (Invitrogen) was added and the cells washed two
times with PBS/0.1% BSA and twice with PBS alone. Labeled AI4 T cells (2  106)
were injected i.v. into female NOD.NON.Thy1a recipients (6–8 weeks of age).
The following day, the recipient mice were injected i.p. with 10 g of anti-
DEC-205/MimA2, 10 g of control Ig/MimA2, or PBS. Peripheral (popliteal,
inguinal, axillary, and brachial) and pancreatic lymph nodes and spleens were
harvested 3 or 12 d later. Transferred cells were identified by positive staining
for both Thy1.2 and CD8. On day 3, proliferation of CFSE-labeled T cells was
assessed by progressive halving of the amount of CFSE fluorescence per cell.
Samples were evaluated by multicolor flow cytometry by using a FACSCalibur
or LSRII (BD Biosciences) with subsequent analysis of data in FlowJo (Tree Star).
Also on day 12, pancreata were harvested and digested with collagenase P,
and islets were hand-picked into 24-well plates (50 islets per well) and cultured
in RPMI medium 1640 supplemented with 50 units/ml hIL-2 to permit T cells to
exit from the islets. Two days later, the cells were harvested, passed through
a 40-M mesh, washed twice, stained for Thy1.2 and CD8, and monitored by
multicolor flow cytometry by using an LSRII.
In vivo T cell proliferation experiments were also performed by using
anti-DEC-205/GP33–41 and CD8 T cells purified from the spleens of NOD.LCMV
TCR Tg mice as described above for AI4.
In Vivo DC Depletion and Anti-DEC-205 Targeting in DC-Depleted Mice. Thy1.2
AI4 cells were purified from the spleens of NOD. AI4 Tg mice as above and
labeled with CFSE, and 2  106 cells were injected i.v. into NOD.CD11c-
DTR.Thy1a mice. Sixteen hours later, recipients received either 4 ng/g DT
(Sigma–Aldrich) i.p. or PBS. Eight hours after the DT injection, all recipients
received an i.p. injection of 10 g of anti-DEC-205/MimA2. After 3 d, lymph
nodes (peripheral and pancreatic) and spleens were evaluated for AI4 prolif-
eration by CFSE dilution as described above.
Determination of the Establishment of Tolerance. Purified AI4 CD8 T cells (2 
106) were transferred to female NOD.NON-Thy1a mice (6–8 weeks of age). The
next day, anti-DEC-205/MimA2 was injected with or without an i.p. injection
of anti-CD40 (25 g of per mouse) and poly I:C (50 g per mouse; Sigma–
Aldrich). Twelve days after antigen injection, mice were boosted with MimA2
peptide (50 g s.c.) suspended in CFA (Sigma–Aldrich). Three days later, 5  106
peripheral lymph node cells were pulsed with the MimA2 peptide for 5 h, then
brefeldin A (BD Biosciences) was added and incubated for 6 h. Cells were then
harvested, washed twice with PBS/2% FBS, and stained for extracellular
Thy1.2. Cells were next fixed and stained for intracellular IFN- after perme-
abilizing the cell with buffer containing saponin (Sigma–Aldrich). Flow cy-
tometry was performed as described above.
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